Welcome to our world. A world where all South Africans have access to world class medicines at affordable prices. A world where affordable healthcare is a right, not a privilege. A world where the final measure of our success is a simple curve – the smile of health regained.

Quick Facts


Largest Company in South Africa

Dosage Forms


Manufacturing Facilities Worldwide



Advancing Healthcare For All


To become the preferred partner in medicine


  • Respect and Pride
  • Passion and Integrity
  • Empowerment
  • Freedom to Succeed
  • Service Excellence
  • Social Responsibility

About Cipla SA

Cipla Medpro, 100%-owned by Cipla India, is one of the country’s leading pharmaceutical companies that produces world class medicines at affordable prices. Today the company is one of the largest pharmaceutical companies in South Africa by volume and third largest by value.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems.

Cipla Medpro

  • Cipla Medpro was founded 18 years ago.
  • Today Cipla Medpro is the fourth largest generic medicines company in South Africa by value & volume.
  • The company was the first in South Africa to launch a three in one ARV combination of a first line regimen (Triomune) in 2006.

Some Key Facts


At Cipla we subscribe to the ethos that all South Africans should have access to world class, yet affordable medicines and to that end we endeavour to produce medicines of superior quality and to introduce these medicines to our society as inexpensively as possible.

Facilities Worldwide

Cipla is one of the largest generic and chronic medicines manufacturers in Asia, with research, development and manufacturing facilities worldwide.

GMP Standards

Cipla International’s advanced technology, stringent production and extensive research and development ensure that Cipla Medpro medicines are manufactured according to the highest international GMP standards.


Cipla’s manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA. Cipla QCIL is one of the first WHO approved manufacturing plant in Sub-Saharan Africa. The company provides one universal standard both domestically and internationally.

Accessable to All

Cipla was responsible for initially lowering the cost of Triple ARV Therapy to less than $1 per day. Cipla is in partnership with the Clinton Foundation to supply ARVs to 3rd world countries.

Respiratory Facts

Cipla has the widest range of respiratory products. Cipla produces 150 million inhalers per year. Cipla has established a Chest Research Foundation to encourage innovative technology and chest research.

Supply & Demand

Cipla was the only company that could supply the USA with enough Ciprofloxacin during the Anthrax scare.

Palliative Care

Cipla has a state of the art Centre for Palliative Care where cancer patients are cared for in their last days, free of charge.